Moreover, the SP‐01 tumor presents an activating mutation in the ERBB4 gene, which is described as a driver of BRAF wild‐type (WT) melanomas [55, 56], and SP‐06 presents an oncogenic NRAS mutation, inactivation of NF2, and a truncating mutation in SMARCA4 (in one allele; Fig. 1A, Table 1). This evidence concerns the gene NF2 and melanoma.